ALUNBRIG is indicated as monotherapy for the treatment of adult patients with:1
- anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (aNSCLC) previously not treated with an ALK inhibitor
- ALK+ aNSCLC previously treated with crizotinib
Efficacy they need, quality of life they want
Up to 75% of patients with ALK+ aNSCLC will develop brain metastases during their disease.2-4
Brain metastases contribute
considerably to the symptom burden in ALK+ aNSCLC, with profound effects on QoL.5,6
Patients need a treatment that delivers both intracranial and
extracranial efficacy.2,3
Superior systemic and intracranial efficacy versus crizotinib in the head-to-head ALTA-1L study in ALK TKI‑naive patients (n=275).7
The recommended dosing regimen is a single, once-daily tablet.¹*
*In circumstances where the dose is modified from the recommended dose, more than one tablet may need to be taken.1 Refer to the Summary of Product Characteristics for further information about the dosing and administration of ALUNBRIG.
ALUNBRIG has a generally manageable tolerability profile.7
ALUNBRIG demonstrated HRQoL benefit versus crizotinib in ALK TKI-naive patients.7,8
HRQoL, health-related quality of life; TKI, tyrosine kinase inhibitor.
1. ALUNBRIG (brigatinib) Summary of Product Characteristics. Available at: medicines.org.uk. Accessed June 2026; 2. Descourt R, Perol M et al. Brigatinib in patients with ALK-positive advanced non‑small‑cell lung cancer pretreated with sequential ALK inhibitors: a multicentric real‑world study (BRIGALK study). Lung Cancer 2019;136:109-114; 3. Huber R M, Hansen K H et al. Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial. J Thorac Oncol 2020;15:404-415; 4. Solomon B J, Besse B et al. Lorlatinib in patients with ALK‑positive non‑small‑cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018;19:1654-1667; 5. Cormie P, Nowak A K et al. The potential role of exercise in neuro‑oncology. Front Oncol 2015;5:85; 6. Guérin A, Sasane M et al. Brain metastases in patients with ALK+ non‑small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ 2015;18:312-322; 7. Camidge D R, Kim H R et al. Brigatinib versus crizotinib in ALK inhibitor‑naive advanced ALK‑positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol 2021;16:2091-2108 (+ suppl); 8. Camidge D R, Kim H R et al. Brigatinib versus crizotinib in advanced ALK inhibitor‑naive ALK‑positive non‑small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 2020;38:3592-3603
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
